C肽通过减轻肠道损伤缓解失血性休克复苏小鼠模型的急性肺部炎症
该研究在12周龄雄性C57/BL6小鼠中建立失血性休克(平均动脉压维持在35 mmHg 60分钟)并复苏(乳酸林格液后输注红细胞)模型,比较加用或不加用C肽的效果。结果显示,与假手术组相比,休克复苏组肠道通透性、细菌移位、肠道损伤、循环HMGB1、肺髓过氧化物酶活性及肺蛋白漏出均增加;加用C肽后上述指标显著降低(p<0.05)。作者认为C肽对失血性休克复苏小鼠具有减轻肠道损伤和功能障碍的有益作用,从而减轻肺部炎症及后续损伤。
要点
- 在12周龄雄性C57/BL6小鼠失血性休克(平均动脉压35 mmHg持续60分钟)复苏模型中,加用C肽组肠道通透性为1.59 ± 1.39 μg FD4/mL,显著低于休克复苏组的6.07 ± 3.41 μg FD4/mL(p<0.05)。
- 加用C肽组细菌移位(脂多糖)为4.53 ± 1.08 pg/mL,显著低于休克复苏组的10.05 ± 4.92 pg/mL(p<0.05)。
- 加用C肽组循环HMGB1为7.27 ± 1.93 ng/mL,显著低于休克复苏组的21.64 ± 14.17 ng/mL(p<0.05)。
- 加用C肽组肺髓过氧化物酶活性为23.73 ± 8.39 mU/g组织,显著低于休克复苏组的34.4 ± 8.91 mU/g组织(p<0.05)。
- 加用C肽组肺蛋白漏出为1.17 ± 0.42 Evans蓝/g组织/分钟,显著低于休克复苏组的2.33 ± 1.16 μg Evans蓝/g组织/分钟(p<0.05)。
适用人群与场景
- 12周龄雄性C57/BL6小鼠,经历失血性休克(平均动脉压维持在35 mmHg持续60分钟)并复苏(乳酸林格液后输注红细胞)。
- 对照组为仅接受假手术、未经历失血性休克的小鼠。
处置流程与药物剂量
- 失血性休克模型:小鼠放血使平均动脉压维持在35 mmHg持续60分钟。
- 复苏方案:先给予乳酸林格液,随后输注红细胞,加用或不加用C肽。
研究设计与关键结果
- 研究类型为动物实验(小鼠模型),比较假手术组、失血性休克复苏组(HS/R)及失血性休克复苏加C肽组(HS/R + C肽)。
- 与假手术组相比,HS/R组肠道通透性升高至6.07 ± 3.41 μg FD4/mL,细菌移位(脂多糖)升高至10.05 ± 4.92 pg/mL,肠道损伤增加。
- HS/R + C肽组肠道通透性为1.59 ± 1.39 μg FD4/mL,细菌移位为4.53 ± 1.08 pg/mL,均显著低于HS/R组(p<0.05),肠道损伤减轻。
- HS/R组循环HMGB1为21.64 ± 14.17 ng/mL,肺髓过氧化物酶活性为34.4 ± 8.91 mU/g组织,肺蛋白漏出为2.33 ± 1.16 μg Evans蓝/g组织/分钟。
- HS/R + C肽组循环HMGB1为7.27 ± 1.93 ng/mL,肺髓过氧化物酶活性为23.73 ± 8.39 mU/g组织,肺蛋白漏出为1.17 ± 0.42 Evans蓝/g组织/分钟,均显著低于HS/R组(p<0.05)。
证据类型、等级与局限
- 证据类型:动物实验(小鼠模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,C肽对失血性休克复苏小鼠具有减轻肠道损伤和功能障碍的有益作用,从而减轻肺部炎症及后续损伤。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The study aims to evaluate whether C-peptide can reduce gut injury during hemorrhagic shock (HS) and resuscitation (R) therefore attenuate shock-induced inflammation and subsequent acute lung injury.
METHODS: Twelve-week-old male mice (C57/BL6) were hemorrhaged (mean arterial blood pressure maintained at 35 mm Hg for 60 minutes) and then resuscitated with Ringer's lactate, followed by red blood cell transfusion with (HS/R) or without C-peptide (HS/R + C-peptide). Mouse gut permeability, bacterial translocation into the circulatory system and intestinal pathology, circulating HMGB1, and acute lung injury were assessed at different times after R. The mice in the control group underwent sham procedures without HS.
RESULTS: Compared to the sham group, the mice in the HS/R group showed increased gut permeability (6.07 ± 3.41 μg of FD4/mL) and bacterial translocation into the circulatory system (10.05 ± 4.92, lipopolysaccharide [LPS] of pg/mL), and increased gut damage; conversely, mice in the HS/R + C-peptide group showed significantly reduced gut permeability (1.59 ± 1.39 μg of FD4/mL; p < 0.05) and bacterial translocation (4.53 ± 1.08 pg of LPS/mL; p < 0.05) with reduced intestine damage. In addition, mice in the HS/R group had increased circulating HMGB1 (21.64 ± 14.17 ng/mL), lung myeloperoxidase) activity (34.4 ± 8.91 mU/g of tissue), and pulmonary protein leakage (2.33 ± 1.16 μg Evans blue/g tissue per minute). Mice in the HS/R + C-peptide group showed decreased HMGB1 (7.27 ± 1.93 ng/mL; p < 0.05), lung myeloperoxidase (23.73 ± 8.39 mU/g of tissue; p < 0.05), and pulmonary protein leakage (1.17 ± 0.42 Evans Blue/g tissue per minute; p < 0.05).
CONCLUSION: Our results indicate that C-peptide exerts beneficial effects to attenuate gut injury and dysfunction, therefore diminishing lung inflammation and subsequent injury in mice with HS and R.
参考来源
- Kao RLC, Xu X, Xenocostas A, et al. C-peptide attenuates acute lung inflammation in a murine model of hemorrhagic shock and resuscitation by reducing gut injury. J Trauma Acute Care Surg. 2017. PMID: 28452895. doi:10.1097/TA.0000000000001539
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。